Target intelligence / Profile preview

UL16 binding protein 3 (ULBP3)

Target
ULBP3
Molecular classification
MHC class I-related protein, Cell surface ligand, Receptor ligand (NKG2D ligand)
01

Overview

UL16 binding protein 3 is a stress-induced cell surface protein related to MHC class I molecules, but structurally lacking the α3 and β2m domains and instead anchored to the membrane by a GPI linkage. It acts as a ligand for the activating NKG2D receptor found on NK cells and subsets of T cells, triggering immune responses against infected, stressed, or malignant cells. ULBP3 can be expressed on the cell surface or released as a soluble form, each modulating immune cell activity in distinct ways. Its expression is tightly regulated and manipulated by various pathogens to aid immune evasion, and its dysregulation is implicated in both tumor immunology and certain autoimmune disorders. ULBP3 is considered a promising therapeutic target for cancer immunotherapy and for anti-viral or immune modulation strategies.

Other names
RAET1NN2DL-3NKG2DL3N2DL3_HUMAN
02

Mechanism of action

NK cell-mediated cytotoxicity through NKG2D engagement; ADCC (antibody-dependent cellular cytotoxicity, when using anti-ULBP3 monoclonal antibodies); Downregulation or soluble ULBP3 can lead to immune escape by decreasing NK cell activity and NKG2D receptor levels

03

Biological functions

Immune response activation (via NKG2D)Regulation of NK cell cytotoxicitySignal transduction (through JAK2, STAT5, ERK after NKG2D engagement)
04

Disease associations

Cancer (prominently expressed on tumor cells and involved in immunosurveillance or immune escape)Autoimmunity (e.g., alopecia areata)Infection (modulated during viral infections for immune evasion by pathogens such as cytomegalovirus and herpesviruses)
05

Safety considerations

Autoimmune side effects due to upregulation of ULBP3 leading to unintended tissue targeting (e.g., alopecia areata)Potential immune exhaustion or suppression when levels of soluble ULBP3 are chronically elevated, reducing NKG2D expression
06

Interacting drugs

Monoclonal antibodies targeting ULBP3 for immunotherapy research (e.g., B2-F1-F1 demonstrated to enhance NK cell activity; not yet approved drugs)
07

Biomarkers

ULBP3 expression (on tumor cells and as soluble protein in serum) can serve as a biomarker for immune status and a possible indicator for cancer immunotherapy selection

Beyond the preview

Go deeper on UL16 binding protein 3 (ULBP3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UL16 binding protein 3 (ULBP3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call